Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
NASDAQ:NTLA

Intellia Therapeutics - NTLA Price Target & Analyst Ratings

$48.26
-1.42 (-2.86%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$47.76
$50.72
50-Day Range
$48.30
$63.47
52-Week Range
$37.08
$130.33
Volume
566,451 shs
Average Volume
1.15 million shs
Market Capitalization
$3.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$110.72

Intellia Therapeutics Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 18 Analyst Ratings

Consensus Analyst Price Target

$110.72
129.43% Upside
High Prediction$180.00
Average Prediction$110.72
Low Prediction$50.00
TypeCurrent
11/28/21 to 11/28/22
1 Month Ago
10/29/21 to 10/29/22
3 Months Ago
8/30/21 to 8/30/22
1 Year Ago
11/28/20 to 11/28/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
16 Buy rating(s)
15 Buy rating(s)
15 Buy rating(s)
14 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$110.72$113.59$128.00$145.47
Predicted Upside129.43% Upside65.75% Upside61.73% Upside15.53% Upside
Get Intellia Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.


NTLA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NTLA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Intellia Therapeutics Stock vs. The Competition

TypeIntellia TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.83
2.66
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside129.43% Upside764.96% Upside14.69% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
391
70.20%
Underperform Votes
166
29.80%
Avg. Outperform Votes
163
66.26%
Avg. Underperform Votes
83
33.74%
Avg. Outperform Votes
853
68.19%
Avg. Underperform Votes
398
31.81%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/14/2022Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Geulah Livshits
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$121.00 ➝ $129.00+142.03%
11/4/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$84.00 ➝ $83.00+58.85%
11/4/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$127.00 ➝ $124.00+140.26%
11/4/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$101.00 ➝ $109.00+111.20%
11/1/2022EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$130.00+146.31%
9/21/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$85.00+35.93%
9/19/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$152.00 ➝ $158.00+155.66%
9/19/2022JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Outperform$106.00 ➝ $111.00+68.92%
9/1/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSell$50.00-16.75%
6/16/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$54.00+30.15%
6/16/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$70.00+71.02%
5/24/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$206.00 ➝ $180.00+311.71%
5/9/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jay Olson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Target$160.00 ➝ $130.00+173.28%
3/7/2022Brookline Capital Acquisition
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$91.00+43.87%
3/7/2022Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Cann
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$91.00+35.98%
3/1/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$146.00 ➝ $83.00-16.03%
2/18/2022William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Prasad
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$144.00+59.29%
1/31/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
1/7/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$171.00+63.53%
11/5/2021HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$171.00 ➝ $182.00+35.88%
10/5/2021Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$170.00+34.09%
9/23/2021Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$173.00+11.40%
8/5/2021Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Butler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$110.00 ➝ $180.00+8.72%
6/28/2021Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$110.00 ➝ $150.00+12.00%
6/28/2021Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joon Lee
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$80.00 ➝ $160.00+80.12%
6/28/2021Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$73.00 ➝ $87.00-2.06%
6/28/2021Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetPositive ➝ Overweight$88.00 ➝ $134.00+50.85%
6/22/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$83.00 ➝ $109.00+38.48%
12/7/2020Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$38.00 ➝ $52.00+19.71%
10/27/2020Summer Street
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
4/2/2020BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Amanda Murphy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$22.00+84.87%
(Data available from 11/28/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












NTLA Price Target - Frequently Asked Questions

What is Intellia Therapeutics's consensus rating and price target?

According to the issued ratings of 18 analysts in the last year, the consensus rating for Intellia Therapeutics stock is Moderate Buy based on the current 1 sell rating, 1 hold rating and 16 buy ratings for NTLA. The average twelve-month price prediction for Intellia Therapeutics is $110.72 with a high price target of $180.00 and a low price target of $50.00. Learn more on NTLA's analyst rating history.

Do Wall Street analysts like Intellia Therapeutics more than its competitors?

Analysts like Intellia Therapeutics more than other Medical companies. The consensus rating for Intellia Therapeutics is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how NTLA compares to other companies.

Do MarketBeat users like Intellia Therapeutics more than its competitors?

MarketBeat users like Intellia Therapeutics more than other Medical companies. 70.20% of MarketBeat users gave Intellia Therapeutics an outperform vote while medical companies recieve an average of 66.26% outperform votes by MarketBeat users.

Does Intellia Therapeutics's stock price have much upside?

According to analysts, Intellia Therapeutics's stock has a predicted upside of 78.73% based on their 12-month price targets.

What analysts cover Intellia Therapeutics?

Stock Ratings Reports and Tools

This page (NASDAQ:NTLA) was last updated on 11/28/2022 by MarketBeat.com Staff